Institution Directory

Clinical trials at Duke University Medical Center

Sites in Durham, NC

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1497

Shown on this page

Current sort

Live official records

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Tacabrutideg, Pirtobrutinib; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 42 more

Conditions: Heart Failure, Biventricular Failure
Interventions: BiVACOR TAH System; Device
Lead sponsor: BiVACOR Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • Durham, North Carolina • Cincinnati, Ohio + 1 more

Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Interventions: The Cleerly CAD Staging System; Device
Lead sponsor: Cleerly, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 7,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 125
States / cities: Chandler, Arizona • Scottsdale, Arizona • Sun City, Arizona + 100 more

Conditions: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radium Ra 223 Dichloride; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 47
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more

Conditions: Atrial Fibrillation
Interventions: PKN605, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Tupelo, Mississippi • Camden, New Jersey • New York, New York + 3 more

Conditions: Abdominal Aortic Aneurysm
Interventions: Nectero EAST System; Drug
Lead sponsor: Nectero Medical, Inc.; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 40
States / cities: Scottsdale, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 32 more

Conditions: Mantle Cell Lymphoma, B Cell Lymphoma
Interventions: Sonrotoclax, Zanubrutinib, Placebo; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more

Conditions: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions: Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 435
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 22
States / cities: Duarte, California • Orange, California • Palo Alto, California + 19 more

Conditions: Ascending Aortic Aneurysm Enlargement, Ascending Aorta Aneurysm
Interventions: Thoracic Aortic Surgery; Procedure
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years to 79 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2035
U.S. locations: 16
States / cities: San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 12 more

Conditions: Congenital Antithrombin Deficiency
Interventions: Atenativ; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Miami, Florida • Peoria, Illinois + 2 more

Conditions: Calcium Release Deficiency Syndrome
Interventions: Not listed
Lead sponsor: Population Health Research Institute; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2050
U.S. locations: 4
States / cities: San Francisco, California • Rochester, Minnesota • Durham, North Carolina + 1 more

About this Duke University Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Duke University Medical Center in Durham, NC as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Duke University Medical Center

Filter and sort this campus

Live official records

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

BiVACOR® Total Artificial Heart Early Feasibility Study

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

Nectero EAST System Clinical Study

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

International CRDS Registry

About this Duke University Medical Center institution page